Post by Nadica (She/Her) on Aug 16, 2024 2:06:26 GMT
Most Patients With MS Have No Risk for Relapse After COVID-19 Vaccination - Published Aug 15, 2024
HealthDay News — For most patients with multiple sclerosis (MS), there is no increased risk for relapse after COVID-19 vaccination, according to a study published online August 14 in Neurology.
Xavier Moisset, MD, PhD, from the Universite Clermont Auvergne in Clermont-Ferrand, France, and colleagues conducted a nationwide study using data from the French National Health Data System to estimate the risk for severe relapse after 1, 2, and 3 (booster) doses of COVID-19 vaccination in patients with MS. A total of 124,545 patients with MS were identified on January 1, 2021; 82% received at least one dose of COVID-19 vaccine until December 31, 2021, with a total of 259,880 doses.
The researchers found that the combined incidence rate ratio was 0.97 (95% CI, 0.91 to 1.03; P =.30) for MS relapse. In various subgroups, including those aged younger than 50 years, with a duration of MS less than 10 years, and using disease-modifying treatments (DMTs), the same absence of risk was confirmed. For patients with high MS activity, especially when not treated, a small increase in relapse risk was seen after a booster dose (incidence rate ratio, 1.39; 95% CI, 1.08 to 1.80).
“These vaccines can be used without any worry about the risk of relapse to provide booster doses to patients for whom they are warranted,” the authors write. “However, particular caution is needed for patients with the highest inflammatory activity in the previous two years, who should first receive DMT.”
Several authors disclosed ties to the pharmaceutical industry.
Article (PAYWALLED): www.neurology.org/doi/10.1212/WNL.0000000000209662
HealthDay News — For most patients with multiple sclerosis (MS), there is no increased risk for relapse after COVID-19 vaccination, according to a study published online August 14 in Neurology.
Xavier Moisset, MD, PhD, from the Universite Clermont Auvergne in Clermont-Ferrand, France, and colleagues conducted a nationwide study using data from the French National Health Data System to estimate the risk for severe relapse after 1, 2, and 3 (booster) doses of COVID-19 vaccination in patients with MS. A total of 124,545 patients with MS were identified on January 1, 2021; 82% received at least one dose of COVID-19 vaccine until December 31, 2021, with a total of 259,880 doses.
The researchers found that the combined incidence rate ratio was 0.97 (95% CI, 0.91 to 1.03; P =.30) for MS relapse. In various subgroups, including those aged younger than 50 years, with a duration of MS less than 10 years, and using disease-modifying treatments (DMTs), the same absence of risk was confirmed. For patients with high MS activity, especially when not treated, a small increase in relapse risk was seen after a booster dose (incidence rate ratio, 1.39; 95% CI, 1.08 to 1.80).
“These vaccines can be used without any worry about the risk of relapse to provide booster doses to patients for whom they are warranted,” the authors write. “However, particular caution is needed for patients with the highest inflammatory activity in the previous two years, who should first receive DMT.”
Several authors disclosed ties to the pharmaceutical industry.
Article (PAYWALLED): www.neurology.org/doi/10.1212/WNL.0000000000209662